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OBJECTIVE 
 
To study the effect of corticosteroids 
on glucose control in preterm 
pregnant patients with diet controlled 
gestational diabetes, and to 
formulate a plan for surveillance and 
treatment in order to reduce 
maternal and neonatal morbidity. 
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METHODS 
 
This retrospective study was 
approved by the University of Iowa 
Hospital and Clinics (UIHC) 
Institutional Review Board. All diet 
controlled gestational diabetic 
patients admitted to our hospital from 
2005-2010 with singleton or multiple 
gestations receiving corticosteroids 
for fetal lung maturity at 24-37 weeks 
gestation were included. Data 
including gestational age at time of 
administration of corticosteroids, 
time interval from corticosteroid 
administration to rise in blood 
glucose, hypoglycemic agent if used 
and length of treatment, gestational 
age at delivery, and maternal 
characteristics such as age, BMI, 
and parity were collected by chart 
review. Statistical analysis was done 
using a computerized database, 
constructed and analyzed with 
WinStar software, release 1.70 
(Anderson Bell, Arvada, CO).  
 
RESULTS 
A total of 3210 patients were 
admitted to UIHC at a preterm 
gestational age and 309 of those 
patients were diabetic by ICD-9 
code. Ninety-six patients were 
eligible for the study in that they had 
an official diagnosis of diabetes and 
there was record of corticosteroid 
administration and blood glucose 
monitoring. Of these 96 patients, 34 
patients had GODMA1. Five of these 
patients had normal blood sugars 
after receiving corticosteroids and 29 
subjects had abnormal blood sugars. 
Six of the 29 patients with abnormal 
blood sugars did not receive 
treatment because their blood 
sugars were not deemed high 
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enough to require treatment. Twenty-
three patients received treatment for 
sustained hyperglycemia. Two 
patients were treated with glyburide 
only and the remaining patients 
required insulin. Three patients 
received glyburide and 
subcutaneous insulin. Twenty-four 
patients required some form of 
insulin. The interval from 
corticosteroid administration to blood 
glucose elevation was 1 hour to 36 
hours. In all but 2 patients, the 
treatment was continued until 
delivery. The gestational age in 
patients that required treatment for 
hyperglycemia (31.77+/-2.5 weeks) 
was significantly greater than those 
not requiring treatment (30.0+/-3.3 
weeks). The mean number of days 
from corticosteroids to delivery was 9 
days. The gestational age at delivery 
was also significantly greater in 
those requiring treatment (33.35+/-2 
weeks) compared to those without 
treatment (31.57+/-3.45 weeks). 
Maternal BMI did not differ 
significantly between treated and 
non-treated patients. Maternal age 
was not significantly different 
between the two groups either.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CONCLUSION 
 
Women with GODMA1 receiving 
corticosteroids will often develop 
hyperglycemia requiring treatment 
with oral agents or insulin. Close 
monitoring of blood glucose levels is 
important for timely initiation of 
treatment. Providers should have a 
low threshold to initiate treatment. 
Patients with more advanced 
gestational age are likely to require 
more aggressive treatment. 
Controlling maternal blood glucose 
carefully in GODMA1 patients is 
important for improved perinatal 
outcome. The best treatment 
regimen has not been established, 
but will likely involve insulin. 
